About Akebia Therapeutics, Inc. - Common Stock (AKBA)
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease. The company is primarily engaged in addressing unmet medical needs in anemia caused by chronic kidney disease, aiming to enhance patient outcomes through its proprietary treatments and drug candidates. Akebia's research and development efforts are centered around creating therapies that improve the management of renal diseases by promoting better health and quality of life for patients suffering from kidney-related conditions. Read More
The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
